Kidney Week 2025 Annual Meeting-Late-Breaking Research Orals

Video Transcription

Video Summary

The session featured multiple “hot topic” kidney studies. Dr. Delphine Cervantes presented Navigate Kidney, a multicenter randomized trial testing a community health worker (CHW) intervention for Latino dialysis patients in five Colorado centers (2020–2022). CHWs met patients biweekly, focusing on trust-building, addressing social/structural barriers, patient-centered education, and self-management. Among 139 participants, the intervention modestly reduced interdialytic weight gain, decreased shortened dialysis sessions, and improved patient activation. Qualitative interviews highlighted practical support around food insecurity (resource provision plus education) and fluid/salt literacy.<br /><br />Dr. Xiaoying Du reported a phase 2 trial of HRS-7535, an oral small-molecule GLP-1 receptor agonist for diabetic kidney disease with persistent albuminuria despite standard care. In 281 participants, the 90 mg dose produced a placebo-adjusted, dose-dependent albuminuria reduction (about 46% reduction from baseline; ~25% placebo-adjusted in those on multiple kidney-protective agents), improved A1c, and showed a GI side-effect profile typical of GLP-1 therapies; eGFR changes appeared mild and transient.<br /><br />Dr. Catherine Tuttle presented the 52-week REMODEL mechanistic semaglutide trial (1 mg weekly). MRI showed significant reductions in renal fat, improved resistive index, and stabilization of fibrosis markers; UACR fell ~40%. Biopsy transcriptomics suggested downregulation of metabolic stress and fibroinflammatory pathways, with reduced NK T-cell proximity to glomeruli.<br /><br />Dr. Rajiv Agarwal summarized CONFIDENCE: empagliflozin, finerenone, or both. Adding empagliflozin did not meaningfully reduce finerenone-associated hyperkalemia; albuminuria benefits persisted regardless of hyperkalemia.<br /><br />Dr. Matthew Weir reported EXPLORE-CKD, a crossover trial of lorundrostat (aldosterone synthase inhibitor) added to ACE/ARB plus SGLT2i, lowering systolic BP (~7.5 mmHg placebo-adjusted) and UACR (~26% placebo-adjusted), with some hyperkalemia.<br /><br />Dr. Brendan Nguyen presented a meta-analysis showing SGLT2 inhibitors reduce CKD progression consistently across eGFR and albuminuria strata, including stage 4 CKD.<br /><br />Finally, Dr. Patrick Mark updated Global Burden of Disease CKD estimates: ~788 million adults with CKD; CKD now the 9th leading cause of death globally, with major regional inequities and a need for better data and implementation of effective therapies.

Asset Subtitle

Moderator(s): Keisha Gibson, Kalani Raphael

Presentation(s):

Efficacy and Safety of the Oral Small-Molecule GLP-1 Receptor Agonist HRS-7535 in Patients with Diabetic Kidney Disease - Xiaoying Du
Mechanistic Effects of Semaglutide on Kidney Disease in Type 2 Diabetes: The REMODEL Trial - Katherine Tuttle
Serum Potassium, Hyperkalemia, and the Effect of Hyperkalemia on Treatment Efficacy with Empagliflozin, Finerenone, or Both: A CONFIDENCE Trial Report - Rajiv Agarwal
Lorundrostat, a Novel Aldosterone Synthase Inhibitor (ASI), in Participants with Uncontrolled Hypertension, CKD, and Albuminuria: Results from Explore-CKD - Matthew Weir
Impact of Glomerular Filtration Rate and Albuminuria on the Effects of SGLT2 Inhibitors on Kidney Outcomes - Brendon Neuen
Global, Regional, and National Burden of CKD in Adults: Updated Systematic Analyses of the Global Burden of Disease Study - Patrick Mark
Community Health Worker Support for Latino Individuals on Dialysis: The Navigate-Kidney Randomized Clinical Trial - Lilia Cervantes

Note: Continuing education credits are not being offered for this session.

Meta Tag

Date 11/7/2025

Pathway 1 Other

Session ID 527926

Keywords

Navigate Kidney trial

community health worker intervention

Latino dialysis patients

interdialytic weight gain

patient activation

HRS-7535 oral GLP-1 receptor agonist

diabetic kidney disease albuminuria

semaglutide REMODEL trial

renal fat MRI

empagliflozin finerenone CONFIDENCE

lorundrostat aldosterone synthase inhibitor

Global Burden of Disease CKD estimates